


THE LANCET SERIES ON ALZHEIMER'S DISEASE

THE NEW DIAGNOSTIC AND TREATMENT LANDSCAPE

Global launch event

September 23, 2025

Geneva University Hospitals



THE LANCET SERIES

ON ALZHEIMER'S DISEASE

In the past century, more than 460 terabytes of literature on Alzheimer's disease have been written—equivalent to 100,000 editions of the Encyclopaedia Britannica—with approximately two-thirds produced in the past 20 years. The recent initial successes of biological drugs for Alzheimer's disease add to this knowledge and herald a new era in the diagnosis and treatment of the disease, as well as a novel approach to cognitive aging in general.

With NI (natural intelligence) and personal expertise, 40 experts from 14 countries across four continents have distilled this vast body of knowledge into three scientific papers published in The Lancet. These papers present the most clinically actionable, patient-relevant, updated, and trusted information on the disease available to date.

The authors acknowledge that anti b-amyloid monoclonal antibodies slow the clinical progression of Alzheimer's, may have potentially severe but manageable adverse effects, and compare favourably with biologics for other diseases concerning efficacy, tolerability, and costs. The use of these drugs must be incorporated into a robust and structured diagnostic journey that includes CSF, PET, and blood biomarkers in addition to traditional cognitive, behavioral assessments, and structural imaging.

They prioritize evidence-based non-pharmacologic and pharmacologic interventions for behavioural symptoms before cholinesterase inhibitors and memantine for cognitive symptoms, the efficacy of which is reaffirmed. The authors finally share the debate within the Alzheimer's community regarding the very definition of the disease, with paramount practical and societal implications, and they propose an innovative framework for secondary prevention in cognitively intact individuals.

References

- ▶ New landscape of the diagnosis of Alzheimer's disease. Lancet. 2025;xxx:xxx-xxx.
- ▶ Treatment for Alzheimer's disease. Lancet. 2025;xxx:xxx-xxx.
- ▶ Alzheimer's outlook: controversies and the foreseeable future. Lancet. 2025;xxx:xxx-xxx.

Programme

September 23, 2025

12:30 Welcome address

12:45 Why a Series on Alzheimer's disease at The Lancet

Richard Horton, The Lancet, London

12:55 The diagnosis of Alzheimer's disease with traditional and blood biomarkers

Frank Jessen, University of Cologne and DZNE, Germany

13:05 The treatment of Alzheimer's disease with traditional and biologic drugs

Nick Fox, University College London and Queen Square Institute of Neurology, UK

13:15 Controversies on and the future of care for Alzheimer's disease

Giovanni B Frisoni, University of Geneva and Geneva University Hospitals, Switzerland

13:25 Video tags from coauthors

13:30 The global impact of The Lancet Series on Alzheimer

Representative from WHO

Chair: Beatriz Gomez Perez Nieves, The Lancet, London

13:40 Questions and answers from journalists and the audience

14:00 Close

Practical information

Time zone

Central Europe Time

In-person participation

By invitation only

Venue

Hôpitaux Universitaires de Genève
SFITS - SWISS Foundation for Innovation and Training
Bâtiment Morier, Rue Gabrielle-Perret-Gentil 4
1205 Genève



Access via public transportation

Bus n° 1, 5, 7, 35 | Stop Hôpital

Bus n° 3 | Stop Claparède

Tram n° 12, 18 | Stop Augustins

Train SL1, SL2, SL3, SL4 | Stop Genève-Champel

Access by car

PARKING Lombard

Online participation

Free via the live stream:



Programme

The programme can be downloaded at:

